The patient's cause of death was unrelated to the study device or procedure.This is being reported as a follow-up to the clinical study.Patient information regarding relevant tests or laboratory data is unknown.This information was not available from the facility.The patient's death was unrelated to the stellarex device or procedure, thus the paclitaxel drug did not cause or contribute to the patient¿s death.Udi and pma numbers are not applicable.This device was used in clinical application prior to being available in the u.S.Report source: foreign- (b)(6) / study name: (b)(4).Combination product is applicable.During the index procedure, the product worked as intended, thus no product evaluation was required.Per the ifu, death is listed as a potential complications/adverse events.
|
It was reported through a clinical study that during the index procedure on (b)(6) 2015, a stellarex catheter was used to treat the target lesion of the left distal sfa.Approximately 29 months post index procedure, it was reported the patient was admitted due to problems with a previous procedure for cholangiocarcinoma.The patient was later diagnosed with gastric outlet obstruction, pneumonia, and hypokalemia.On (b)(6) 2017, a gastrojejunostomy was created.On (b)(6) 2017, the patient expired with high levels of bilirubin and possible evidence of recurrent cholangiocarcinoma.The physician indicated this is not related to the study device or procedure.
|